样式: 排序: IF: - GO 导出 标记为已读
-
Adamts1 and Cyst Expansion in Polycystic Kidney Disease. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-08 Vijayakumar R Kakade,Zafer Akman,Manga Motrapu,Marcelo F Cassini,Leyuan Xu,Gilbert Moeckel,Stefan Somlo,Lloyd G Cantley
BACKGROUND Autosomal dominant polycystic kidney disease (ADPKD) is characterized by mutations in either the Pkd1 or Pkd2 genes leading to progressive cyst growth and often kidney failure. We have previously demonstrated that tubules can enlarge following loss of Pkd1 without an increase in tubular cell numbers, suggesting that tubular basement membrane remodeling is important for cystic dilation. RNA
-
Baseline Diastolic BP and BP-Lowering Effects on Cardiovascular Outcomes and All-Cause Mortality: A Meta Analysis. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-08 Amara Sarwal,Robert E Boucher,Sydney E Hartsell,Guo Wei,Jincheng Shen,Glenn M Chertow,Paul K Whelton,Alfred K Cheung,John William McEvoy,Tom Greene,Srinivasan Beddhu
BACKGROUND Lowering blood pressure (BP) in persons with low diastolic BP could be harmful. Hence, we examined whether baseline diastolic BP modifies the effects of BP lowering on clinical outcomes in a meta-analysis of five large BP lowering trials. METHODS In a study-level meta-analysis based on individual participant data of the Systolic Blood Pressure Intervention Trial (N = 9361), the Action to
-
Is IgA Class Switching Epigenetically Wired?: Untangling the Evidence. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-05 Ghazal Z Quinn,Katalin Susztak
-
Selective Cytopheretic Device (QUELimmuneTM): A Leukocyte Processing, Immunomodulatory Device. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-05 Christopher J Pino,Kimberly A Johnston,Angela J Westover,H David Humes
-
Involving Patients in the Design of Clinical Trials in Nephrology. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-05 Andrea K Viecelli,Allison Jaure,Katharine Hegerty,Nicole Scholes-Robertson
-
External Validation of an Electronic Health Record-Based Diagnostic Model for Histological Acute Tubulointerstitial Nephritis. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-05 Dennis G Moledina,Kyra Shelton,Steven Menez,Abinet M Aklilu,Yu Yamamoto,Bashar A Kadhim,Melissa Shaw,Candice Kent,Amrita Makhijani,David Hu,Michael Simonov,Kyle O'Connor,Jack Bitzel,Heather Thiessen-Philbrook,F Perry Wilson,Chirag R Parikh
BACKGROUND Accurate diagnosis of acute tubulointerstitial nephritis (AIN) often requires a kidney biopsy. We previously developed a diagnostic statistical model for predicting biopsy-confirmed AIN by combining four laboratory tests after evaluating over 150 potential predictors from the electronic health record. Here, we validate this diagnostic model in two biopsy-based cohorts at Johns Hopkins Hospital
-
Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis: A Pilot Randomized Controlled Trial. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-04 Ziv Harel,Brendan Smyth,Sunil V Badve,Daniel Blum,William Beaubien-Souligny,Samuel A Silver,Edward Clark,Rita Suri,Thomas A Mavrakanas,Joanna Sasal,Bhanu Prasad,John Eikelboom,Karthik Tennankore,Claudio Rigatto,Ivana Prce,Francois Madore,Fabrice Mac-Way,Andrew Steele,Yangmin Zeng,Michelle Sholzberg,Paul Dorian,Andrew T Yan,Manish M Sood,David J Gladstone,Eric Tseng,Abhijat Kitchlu,Michael Walsh,Danny
BACKGROUND Atrial fibrillation is common in individuals receiving dialysis. The role of oral anticoagulation in this population is uncertain given its exclusion from previous seminal clinical trials. Our objective was to determine the feasibility of performing a large definitive trial to establish the optimal anticoagulation strategy in individuals with atrial fibrillation receiving dialysis. METHODS
-
Population Health Management and Guideline-Concordant Care in CKD: A Secondary Analysis of K-CHAMP. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-01 Melanie R Weltman,Linda-Marie U Lavenburg,Zhuoheng Han,Alaa A Alghwiri,Mitra Mosslemi,Bruce L Rollman,Gary S Fischer,Thomas D Nolin,Jonathan G Yabes,Manisha Jhamb
BACKGROUND Gaps in guideline-concordant care for chronic kidney disease (CKD) lead to poor outcomes. The Kidney Coordinated HeAlth Management Partnership (K-CHAMP) cluster randomized trial tested the effect of a population health management intervention versus usual care on CKD progression and evidence-based care delivery in the primary care setting. METHODS K-CHAMP included adults aged 18-85 years
-
Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-01 Vikas S Sridhar,Ayodele Odutayo,Satish Garg,Thomas Danne,Alessandro Doria,Michael Mauer,Michael J Davies,Phillip Banks,Manon Girard,David Z I Cherney
BACKGROUND This analysis evaluated the efficacy and safety of sotagliflozin, a dual SGLT1&2 inhibitor, added to insulin in patients with type 1 diabetes and chronic kidney disease (CKD). METHODS We used data from the 52-week pooled inTandem1&2 trials and the 24-week inTandem3 trial to assess the effects of sotagliflozin (200mg [inTandem 1&2 only] or 400mg daily) versus placebo on glycated hemoglobin
-
Beyond Childhood: The Lifelong Kidney Risks for Children with Posterior Urethral Valves. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-31 Elizabeth A K Hunt,Deborah R Stein
-
Long-Term Benefits and Safety of Statins in Patients with Kidney Failure: A Target Trial Emulation Study. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-31 Franco Wing-Tak Cheng,Wanchun Xu,Sydney C W Tang,Eric Yuk-Fai Wan
BACKGROUND Patients with kidney failure are at elevated risk of cardiovascular diseases. Although statins were commonly used to mitigate cardiovascular disease risk among the population with high risk, the evidence for initiating statin therapy among patients with kidney failure remains inconclusive. This study aimed to investigate the long-term benefits and risks associated with statin therapy in
-
Using Simulation to Optimize the Design of Adaptive Clinical Trials. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-31 Cal H Robinson,Rulan S Parekh,Brian H Cuthbertson,Eddy Fan,Yongdong Ouyang,Anna Heath
-
SPRINTing to Conclusions: Evaluating the Long-Term Effects of Intensive BP Control on Kidney Health. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-30 Gregory L Hundemer,Manish M Sood
-
Long-Term Kidney Outcomes after Pediatric Acute Kidney Injury: Future Studies Need to Explore Further. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-29 Qi Gao,Honglan Wei,Yanqin Li,Licong Su
-
Authors' Reply: Long-Term Kidney Outcomes after Pediatric Acute Kidney Injury: Future Studies Need to Explore Further. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-29 Cal H Robinson,Rahul Chanchlani
-
From Despair to Promise: The Dawn of Novel Treatment in IgA Nephropathy. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-26 Sydney C W Tang,Girish N Nadkarni
-
The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-26 Hiddo J L Heerspink,Xiaoying Du,Yan Xu,Yanning Zhang,Bin Liu,Guangyu Bi,Chengyun Xu,Qun Luo,Henglan Wu,Jianxin Wan,Liou Cao,Rong Wang,Qiuling Fan,Hong Cheng,Lixia Xu,Jiyi Huang,Aimin Zhong,Qingfeng Peng,Yongjiang Hei,Yiwei Wang,Bo Zhou,Liqin Zhang,Jianghua Chen
-
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-26 Jonathan Barratt,Sean J Barbour,Robert M Brenner,Kerry Cooper,Xuelian Wei,Necmi Eren,Jürgen Floege,Vivekanand Jha,Sung Gyun Kim,Bart Maes,Richard K S Phoon,Harmeet Singh,Vladimír Tesař,Richard Lafayette,
-
In Vitro Simulation of Hemodialysis Reveals Hemodialysis-Associated Pro-Arrhythmic Effects in a Human Cardiomyocyte Model. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-25 Thomas Körtl,Niklas Hankowitz,Laura Stengel,Oliver Pfeuffer,Dominic Riedl,Frank Schweda,Katrin Streckfuß-Bömeke,Samuel Sossalla
-
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-25 Richard Lafayette,James Tumlin,Roberta Fenoglio,Jessica Kaufeld,Miguel Ángel Pérez Valdivia,Mai-Szu Wu,Shih-Han Susan Huang,Eric Alamartine,Sung Gyun Kim,Min Yee,Andreas Kateifides,Kara Rice,Katherine Garlo,Jonathan Barratt,
-
Improving Processes of Care after Acute Kidney Injury. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-24 L Parker Gregg,David E Leaf
-
Advancing Community Care and Access to Follow-Up after Acute Kidney Injury Hospitalization: A Randomized Clinical Trial. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-24 Neesh Pannu,Kerry A McBrien,Zhi Tan,Nasreen Ahmad,Coralea Bignell,Eleanor Benterud,Taylor Palechuk,Tyrone G Harrison,Braden J Manns,Nairne Scott-Douglas,Matthew T James
-
Simulation-Based Sample Size Estimation in Clinical Trials in Nephrology. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-24 Leila R Zelnick
-
I-mfa, Mesangial Cell TRPC1 Channel, and Regulation of Glomerular Filtration Rate. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-24 Yu Tao,Muyi Liu,Garland Siebert,Paromita Das-Earl,Deena Ibrahim,Nicole Crowe,Suilan Zheng,Rong Ma
BACKGROUND Inhibitor of MyoD family A (I-mfa) is a cytosolic protein. Its function in kidney is unknown. The aim of the present study was to examine the regulatory role of I-mfa on glomerular filtration rate (GFR). METHODS GFR was measured by transdermal measurement of FITC-sinitrin clearance in conscious wild type (WT) and I-mfa knockout (KO) mice. Cell contractility was assessed in a single human
-
GALNT3 in Ischemia-Reperfusion Injury of the Kidney. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-24 Wenwen Wu,Ying Fu,Honglin Li,Yu Xiang,Yuqing Zeng,Juan Cai,Zheng Dong
BACKGROUND Damages to subcellular organelles, such as mitochondria and endoplasmic reticulum, are well-recognized in tubular cell injury and death in acute kidney injury (AKI). However, the changes and involvement of Golgi apparatus are much less known. Here, we report the regulation and role of N-acetylgalactosaminyltransferase-3 (GALNT3), a key enzyme for protein glycosylation in Golgi apparatus
-
The Physicochemical Approach to Acid-Base Balance: A Critique. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-24 Man S Oh,Jaime Uribarri
-
Transmembrane Serine Protease 2 and Proteolytic Activation of the Epithelial Sodium Channel in Mouse Kidney. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-23 Florian Sure,Sara Afonso,Daniel Essigke,Paul Schmidt,M Zaher Kalo,Viatcheslav Nesterov,Alicia Kißler,Marko Bertog,Ralf Rinke,Sabine Wittmann,Katharina A E Broeker,Thomas Gramberg,Ferruh Artunc,Christoph Korbmacher,Alexandr V Ilyaskin
BACKGROUND The renal epithelial sodium channel (ENaC) is essential for sodium balance and blood pressure control. ENaC undergoes complex proteolytic activation by not yet clearly identified tubular proteases. Here, we examined a potential role of transmembrane serine protease 2 (TMPRSS2). METHODS Murine ENaC and TMPRSS2 were (co-)expressed in Xenopus laevis oocytes. ENaC cleavage and function were
-
Piezo, Nephrocyte Function, and Slit Diaphragm Maintenance in Drosophila. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-17 Yunpo Zhao,Jianli Duan,Iden D Han,Joyce van de Leemput,Patricio E Ray,Zhe Han
BACKGROUND The Piezo gene encodes a highly conserved cell membrane protein responsible for sensing pressure. The glomerular kidney and the slit diaphragm filtration structure depend on pressure for filtration. However, how Piezo is involved in kidney function and in maintaining the slit diaphragm filtration structure is not clear. METHODS We used Drosophila pericardial nephrocytes, filtration kidney
-
Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-16 Philipp Gauckler,Anna Matyjek,Seleni Kapsia,Smaragdi Marinaki,Luis F Quintana,Montserrat M Diaz,Catherine King,Siân Griffin,Raja Ramachandran,Balazs Odler,Kathrin Eller,Ayşe Serra Artan,Safak Mirioglu,Martin Busch,Maxi Schaepe,Kultigin Turkmen,Chee Kay Cheung,Ruth J Pepper,Gema Fernandez Juarez,Julio Pascual,Pilar Auñón,Clara García-Carro,Antolina Rodriguez,Federico Alberici,Leonella Luzardo,Natalia
BACKGROUND Long-term outcomes of rituximab-treated adult patients with podocytopathies (either minimal change disease or focal segmental glomerulosclerosis) are largely unknown. METHODS A retrospective study at 30 nephrology departments from 15 countries worldwide included rituximab-treated adults with primary podocytopathies and a minimum clinical follow-up of 36 months. The primary outcome was relapse-free
-
MQ232, A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-16 Goran Stanajic-Petrovic,Mathilde Keck,Peggy Barbe,Apolline Urman,Evelyne Correia,Pierre Isnard,Jean-Paul Duong Van Huyen,Khawla Chmeis,Sékou Siramakan Diarra,Stefano Palea,Frederic Theodoro,Anvi-Laëtitia Nguyen,Florence Castelli,Alain Pruvost,Wenchao Zhao,Christiane Mendre,Bernard Mouillac,Frank Bienaimé,Philippe Robin,Pascal Kessler,Catherine Llorens-Cortes,Denis Servent,Hervé Nozach,Bernard Maillère
BACKGROUND Vaptans were developed at the end of the previous century as V2R antagonists. Tolvaptan is the most prescribed vaptan for hyponatremia and the autosomal polycystic kidney disease (ADPKD). However, its use is not as widespread as it should be due to price issues, a narrow therapeutic window and some side effects. With the aim of discovering new efficient and safer V2R antagonists, we screened
-
The Potential Outcome-Modification Influences Introduced by ESKD Life Plan on eGFR Slopes. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-16 Kuo-Chin Hung,Chia-Ter Chao
-
Competing and Noncompeting Risk Models for Predicting Kidney Allograft Failure. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-16 Agathe Truchot,Marc Raynaud,Ilkka Helanterä,Olivier Aubert,Nassim Kamar,Gillian Divard,Brad Astor,Christophe Legendre,Alexandre Hertig,Matthias Buchler,Marta Crespo,Enver Akalin,Gervasio Soler Pujol,Maria Cristina Ribeiro de Castro,Arthur J Matas,Camilo Ulloa,Stanley C Jordan,Edmund Huang,Ivana Juric,Nikolina Basic-Jukic,Maarten Coemans,Maarten Naesens,John J Friedewald,Helio Tedesco Silva,Carmen Lefaucheur
BACKGROUND Prognostic models are becoming increasingly relevant in clinical trials as potential surrogate endpoints, and for patient management as clinical decision support tools. However, the impact of competing risks on model performance remains poorly investigated. We aimed to carefully assess the performance of competing risk and noncompeting risk models in the context of kidney transplantation
-
Toward a Restrictive Use of Plasma Exchanges in Thrombotic Microangiopathies. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-16 Marie Frimat,Nora Schwotzer,François Provôt,Fadi Fakhouri
-
Authors' Reply: The Potential Outcome-Modification Influences Introduced by ESKD Life Plan on eGFR Slopes. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-16 Abdel-Hay Tabcheh,Julie Boucquemont,Roberto Pecoits-Filho,Natalia Alencar De Pinho,
-
LAPTM5: A Novel Target in an Old Fight against Tubular Senescence. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-15 Michael S Balzer
-
Premature Conclusion that Sodium-Glucose Cotransporter-2 Inhibitors Improve Kidney Outcomes in Patients with Heart Failure. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-14 Fan Zhang,Xianwen Zhang,Yifei Zhong
-
The Association of Outdoor Temperature with Severe Hyponatremia: A Study Based on the Stockholm Sodium Cohort. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-14 Issa Issa,Jakob Skov,Henrik Falhammar,Jonatan Lindh,Buster Mannheimer
BACKGROUND Hyponatremia is a common condition with unspecific symptoms and a complicated etiology. The impact of outdoor temperature on hyponatremia is not well-studied and varies depending on the climate and location. This study aimed to investigate the association between outdoor temperature and the prevalence of severe hyponatremia. METHODS This retrospective register-based cohort study based on
-
Urinary Cytokeratin 20 as a Biomarker for AKI-CKD Transition among Patients with Acute Decompensated Heart Failure and Acute Kidney Injury. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-11 Han Ouyang,Rui Ma,Xiaobing Yang,Chunbo Chen,Xin Xu,Jianwei Tian,Jun Liu,Yan Zha,Huafeng Liu,Tiecheng Yang,Fan Fan Hou
BACKGROUND Predicting the risk of AKI-CKD transition remains a major challenge in management of acute decompensated heart failure and AKI. This study investigated the clinical utility of urinary cytokeratin 20 (CK20), a novel biomarker reflecting severity of histological acute tubular injury, for identifying patients at risk of AKI-CKD progression. METHODS This prospective cohort study included a Test
-
Safety and Efficacy of Avacopan in Patients with C3 Glomerulopathy: Randomized, Double-Blind Clinical Trial. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-11 Andrew S Bomback,Leal C Herlitz,Priyanka Punit Kedia,Jeffrey Petersen,Huibin Yue,Richard A Lafayette
BACKGROUND Complement 3 (C3) glomerulopathy is a rare autoimmune disorder characterized by activation of the alternative complement pathway with isolated or dominant C3 deposition in glomeruli. Patients with C3 glomerulopathy may develop progressive deterioration in kidney function and kidney failure. METHODS We studied the safety and efficacy of avacopan 30 mg twice daily in patients with C3 glomerulopathy
-
Targeting KLF2 as a Novel Therapy for Glomerular Endothelial Cell Injury in Diabetic Kidney Disease. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-09 Lulin Min,Yixin Chen,Ruijie Liu,Zhengzhe Li,Leyi Gu,Sandeep Mallipattu,Bhaskar Das,Kyung Lee,John Cijiang He,Fang Zhong
BACKGROUND DKD is a microvascular disease, and glomerular endothelial cell injury is a key pathological event in DKD development. Through unbiased screening of glomerular transcriptomes, we previously identified KLF2 as a highly regulated gene in diabetic kidneys. KLF2 exhibits protective effects in endothelial cells by inhibiting inflammation, thrombotic activation, and angiogenesis, all of which
-
Self-Supervised Learning for Feature Extraction from Glomerular Images and Disease Classification with Minimal Annotations. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-09 Masatoshi Abe,Hirohiko Niioka,Ayumi Matsumoto,Yusuke Katsuma,Atsuhiro Imai,Hiroki Okushima,Shingo Ozaki,Naohiko Fujii,Kazumasa Oka,Yusuke Sakaguchi,Kazunori Inoue,Yoshitaka Isaka,Isao Matsui
BACKGROUND Deep learning has great potential in digital kidney pathology. However, its effectiveness depends heavily on the availability of extensively labeled datasets, which are often limited due to the specialized knowledge and time required for their creation. This limitation hinders the widespread application of deep learning for the analysis of kidney biopsy images. METHODS We applied self-distillation
-
Autoantibodies Targeting Proteasome Subunit Alpha Type 1 in Autoimmune Podocytopathies. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-09 Huihui Liu,Chao Zhou,Dongjie Wang,Hanyan Meng,Shifan Zhu,Jiayu Zhang,Jianhua Mao,Qing Ye
BACKGROUND The antibody against proteasome subunit alpha type 1 (PSMA1) is a podocyte autoantibody in idiopathic nephrotic syndrome (INS) children identified in our previous study. The aim of this study was to explore the characteristics of INS in children and the mechanism underlying its involvement in the development of INS. METHODS The levels of serum anti-PSMA1 autoantibodies in children were detected
-
Acetazolamide Therapy and Kidney Function in Persons with Nonalbuminuric Diabetes Mellitus Type 1. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-08 Charles Ginsberg,Jesse C Seegmiller,Volker Vallon,Sami SeungMi Jin,Robert L Thomas,Schafer C Boeder,Jeremy Pettus,Joachim H Ix
BACKGROUND Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower the risk of kidney failure in persons with type 2 diabetes. The presumed mechanism of action is through greater delivery of sodium to the distal tubule, activation of tubuloglomerular feedback which lowers glomerular filtration rate (GFR) and intra-glomerular pressure. SGLT2is are not approved for use in persons with type 1 diabetes
-
Role of Z-DNA Binding Protein 1 Sensing Mitochondrial Z-DNA and Triggering Necroptosis in Oxalate-Induced Acute Kidney Injury. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-07 Caiming Chen,Jingzhi Xie,Zhimin Chen,Keng Ye,Chengkun Wu,Xingchen Dai,Ying Yuan,Yujiao Lin,Yujia Wang,Hong Chen,Jianfeng Wu,Huabin Ma,Yanfang Xu
BACKGROUND Calcium oxalate-induced acute kidney injury is a severe condition in which the kidneys suffer rapid damage due to the deposition of oxalate crystals. Known factors contributing to cell death induced by calcium oxalate include receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain-like (MLKL) protein dependent necroptosis, as well as necrosis involving peptidylprolyl
-
Natural History and Clinicopathological Associations of TRPC6-Associated Podocytopathy. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-01 Benjamin Wooden,Andrew Beenken,Elena Martinelli,Ken Saida,Andrea L Knob,Juntao Ke,Isabella Pisani,Gina Jin,Brandon Lane,Adele Mitrotti,Elizabeth Colby,Tze Y Lim,Francesca Guglielmi,Amy J Osborne,Dina F Ahram,Chen Wang,Farid Armand,Francesca Zanoni,Andrew S Bomback,Marco Delsante,Gerald B Appel,Massimo R A Ferrari,Jeremiah Martino,Sunil Sahdeo,David Breckenridge,Slavé Petrovski,Dirk S Paul,Gentzon Hall
BACKGROUND Understanding the genetic basis of human diseases has become integral to drug development and precision medicine. Recent advancements have enabled the identification of molecular pathways driving diseases, leading to targeted treatment strategies. The increasing investment in rare diseases by the biotech industry underscores the importance of genetic evidence in drug discovery and approval
-
Let Food Be Thy Medicine: Potential of Dietary Management in Cystinosis J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-01 Elena Levtchenko, Fanny Oliveira Arcolino
An abstract is unavailable.
-
Numerical Flow Simulations of the Shear Stress Forces Arising in Filtration Slits during Glomerular Filtration in Rat Kidney. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-30 Alexander Fuhrmann,Balazs Pritz,Karlhans Endlich,Wilhelm Kriz
BACKGROUND The flow dynamic forces during glomerular filtration challenging the fixation of podocytes to the GBM are insufficiently understood. METHODS Numerical flow simulations were used to estimate these forces in the rat kidney. Simulations were run with a 3D model of the slit diaphragm as a zipper structure according to Rodewald and Karnovsky 1. The GBM was modeled as a porous medium. RESULTS
-
Damage-Associated Molecular Patterns and Pattern Recognition Receptors in the Podocyte. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-27 Robert L Myette,Mayra Trentin-Sonoda,Chloé Landry,Chet E Holterman,Tony Lin,Dylan Burger,Christopher R J Kennedy
Podocytes possess immune system components allowing for a variety of innate responses to endogenous and exogenous stimuli. Recently, several groups have linked inappropriate innate immune signaling to podocyte injury, particularly chronic, sustained injury; however, the immune capabilities of podocytes have not been fully elucidated. Damage-associated molecular patterns (DAMPs) are endogenous danger
-
Treating the Untreatable: Antisense Oligonucleotides as an Individualized Therapy for Rare Genetic Kidney Diseases. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-27 Cedrik Tekendo-Ngongang,Joseph G Gleeson,Laurence Mignon
-
Functional Characterization of Anti-C3bBb Autoantibodies and C3 Glomerulopathy Phenotype. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-26 Julia Roquigny,Marie-Sophie Meuleman,Carine El Sissy,Mathilde Cailliez,Aude Servais,Gwenaelle Roussey,Véronique Baudouin,Stéphane Decramer,François Nobili,Alain Wynckel,Anne-Laure Sellier Leclerc,Anne-Laure Lapeyraque,Paula Vieira Martins,Seppo Meri,Marie-Agnès Dragon-Durey,Sophie Chauvet,Véronique Frémeaux-Bacchi
BACKGROUND C3 nephritic factors, i.e. autoantibodies that stabilize the C3 convertase of the alternative pathway are the most frequent acquired abnormality in C3 glomerulopathy and primary immunoglobulin-mediated membranoproliferative GN (Ig-MPGN). METHODS Our study included 27 patients with C3 glomerulopathy (n=21) or Ig-MPGN (n=6), of whom 78% were children at disease onset. At the time of sampling
-
Proteomic Assessment of the Risk of Secondary Cardiovascular Events among Individuals with CKD. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-26 Rajat Deo,Ruth F Dubin,Yue Ren,Jianqiao Wang,Harold Feldman,Haochang Shou,Josef Coresh,Morgan E Grams,Aditya L Surapaneni,Jordana B Cohen,Mayank Kansal,Mahboob Rahman,Mirela Dobre,Jiang He,Tanika Kelly,Alan S Go,Paul L Kimmel,Ramachandran S Vasan,Mark R Segal,Hongzhe Li,Peter Ganz
BACKGROUND Cardiovascular risk models have been developed primarily for incident events. Well-performing models are lacking to predict secondary cardiovascular events among people with a history of coronary heart disease, stroke, or heart failure who also have chronic kidney disease (CKD). We sought to develop a proteomics-based risk score for cardiovascular events in individuals with CKD and a history
-
Learning from Negative Trials for Diabetic Kidney Disease J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-26 Rhian M. Touyz
An abstract is unavailable.
-
Systematic Screening of Autosomal Dominant Tubulointerstitial Kidney Disease- MUC1 27dupC Pathogenic Variant through Exome Sequencing. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-26 Ilias Bensouna,Thomas Robert,Xavier Vanhoye,Marine Dancer,Laure Raymond,Pierre Delaugère,Pascale Hilbert,Hugues Richard,Laurent Mesnard
BACKGROUND The MUC1 gene is associated with autosomal dominant tubulointerstitial kidney disease (ADTKD), leading to CKD. Current methods of sequencing, like exome sequencing, rarely detect MUC1 pathogenic variants because of the variable number of tandem repeats (VNTR) in MUC1 exon2. We demonstrated that combining fast read filtering with a sensitive VNTR genotyping strategy enables systematic screening
-
Long Shadows: Understanding the Lifelong Risk of Acute Kidney Injury in Childhood J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-25 Emily J. See, Catherine Quinlan
An abstract is unavailable.
-
Production of Acetylcholine by Podocytes and its Protection from Kidney Injury in GN. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-20 Luan D Truong,Jessica Trostel,Carlos Roncal,Gabriel Cara-Fuentes,Makoto Miyazaki,Shinobu Miyazaki-Anzai,Ana Andres-Hernando,Fumihiko Sasai,Miguel Lanaspa,Richard J Johnson,Gabriela E Garcia
BACKGROUND One of the most important factors modulating endothelial health is acetylcholine, and while it is associated as a cholinergic neurotransmitter; it is also expressed by non-neuronal cells. However, its role in the kidney, which does not receive cholinergic innervation, remains unknown. METHODS To determine if acetylcholine is produced in the kidney, we used ChAT(BAC)-eGFP (ChAT mice) transgenic
-
Cardiac Localized Polycystin-2 in the Natriuretic Peptide Signaling Pathway and Hypertension. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-20 Karla M Márquez-Nogueras,Brandon Elliott,Paula Thuo,Elisabeth DiNello,Ryne M Knutila,Geena E Fritzmann,Virdjinija Vuchkovska,Sarah Flury,Monte Willis,Arlene B Chapman,Quan Cao,David Y Barefield,Ivana Y Kuo
BACKGROUND Hypertension is seen in 70% of autosomal dominant polycystic kidney disease (ADPKD) patients by the age of 30 prior to decline in kidney function. However, cardiac origins of hypertension, such as the natriuretic peptide signaling pathway, have not been fully investigated. We hypothesized that cardiomyocyte-localized polycystin proteins contribute to production of natriuretic peptides, and
-
Posoleucel for BK Polyomavirus in Kidney Transplant Recipients. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-20 Maud Wilhelm,Anne Geng,Stefan Schaub,Hans H Hirsch
-
ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-18 T. Alp Ikizler, Holly J. Kramer, Srinivasan Beddhu, Alex R. Chang, Allon N. Friedman, Meera N. Harhay, Elizabeth Yakes Jimenez, Brandon Kistler, Aleksandra Kukla, Kristin Larson, LindaMarie U. Lavenburg, Sankar Dass Navaneethan, John Ortiz, Rocio I. Pereira, David B. Sarwer, Philip R. Schauer, Evan M. Zeitler, for the ASN Kidney Health Guidance Workgroup on Obesity and Kidney Diseases
An abstract is unavailable.
-
Ascites: Under- and Overfill: Is Amiloride the Answer? J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-11 Detlef Bockenhauer, Giulia Florio
An abstract is unavailable.
-
In Memoriam of Barry M. Brenner, MD: October 4, 1937, to August 6, 2024 J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-09 Robert M. Brenner, Barry M. Brenner, Richard J. Glassock
An abstract is unavailable.